PURPOSE: Increased expression of αvβ3/αvβ5 integrin is involved in angiogenesis and the inflammatory process in atherosclerotic plaques. The novel 68Ga-DOTA-RGD peptide binds with high affinity to αvβ3/αvβ5 integrin. The aim of this study was to investigate the uptake of the 68Ga-DOTA-RGD peptide in atherosclerotic plaques. METHODS: Uptake of intravenously administered 68Ga-DOTA-RGD peptide was studied ex vivo in excised tissue samples and aortic sections of LDLR-/-ApoB100/100 atherosclerotic mice. The uptake of the tracer in aortic cryosections was examined by using digital autoradiography. Subsequently, the autoradiographs were combined with histological and immunohistological analysis of the sections. RESULTS: DOTA-RGD peptide was successfully labelled with the generator-produced 68Ga. The tracer had reasonably good specific radioactivity (8.7 ± 1.1 GBq/μmol) and was quite stable in vivo. According to ex vivo biodistribution results, 68Ga-DOTA-RGD was cleared rapidly from the blood circulation and excreted through the kidneys to the urine with high radioactivity in the intestine, lungs, spleen and liver. Autoradiography results showed significantly higher uptake of 68Ga-DOTA-RGD peptide in the atherosclerotic plaques compared to healthy vessel wall (mean ratio ± SD 1.4 ± 0.1, p = 0.0004). Conclusion We observed that 68Ga-DOTA-RGD is accumulated into the plaques of atherosclerotic mice. However, this data only shows the feasibility of the approach, while the clinical significance still remains to be proven. Further studies are warranted to assess the uptake of this tracer into human atherosclerotic plaques.
PURPOSE: Increased expression of αvβ3/αvβ5 integrin is involved in angiogenesis and the inflammatory process in atherosclerotic plaques. The novel 68Ga-DOTA-RGD peptide binds with high affinity to αvβ3/αvβ5 integrin. The aim of this study was to investigate the uptake of the 68Ga-DOTA-RGD peptide in atherosclerotic plaques. METHODS: Uptake of intravenously administered 68Ga-DOTA-RGD peptide was studied ex vivo in excised tissue samples and aortic sections of LDLR-/-ApoB100/100 atheroscleroticmice. The uptake of the tracer in aortic cryosections was examined by using digital autoradiography. Subsequently, the autoradiographs were combined with histological and immunohistological analysis of the sections. RESULTS: DOTA-RGD peptide was successfully labelled with the generator-produced 68Ga. The tracer had reasonably good specific radioactivity (8.7 ± 1.1 GBq/μmol) and was quite stable in vivo. According to ex vivo biodistribution results, 68Ga-DOTA-RGD was cleared rapidly from the blood circulation and excreted through the kidneys to the urine with high radioactivity in the intestine, lungs, spleen and liver. Autoradiography results showed significantly higher uptake of 68Ga-DOTA-RGD peptide in the atherosclerotic plaques compared to healthy vessel wall (mean ratio ± SD 1.4 ± 0.1, p = 0.0004). Conclusion We observed that 68Ga-DOTA-RGD is accumulated into the plaques of atheroscleroticmice. However, this data only shows the feasibility of the approach, while the clinical significance still remains to be proven. Further studies are warranted to assess the uptake of this tracer into humanatherosclerotic plaques.
Authors: P Dufourcq; H Louis; C Moreau; D Daret; M R Boisseau; J M Lamazière; J Bonnet Journal: Arterioscler Thromb Vasc Biol Date: 1998-02 Impact factor: 8.311
Authors: F Paulhe; C Racaud-Sultan; A Ragab; C Albiges-Rizo; H Chap; N Iberg; O Morand; B Perret Journal: J Biol Chem Date: 2001-09-10 Impact factor: 5.157
Authors: Ingrid Dijkgraaf; John A W Kruijtzer; Shuang Liu; Annemieke C Soede; Wim J G Oyen; Frans H M Corstens; Rob M J Liskamp; Otto C Boerman Journal: Eur J Nucl Med Mol Imaging Date: 2006-08-15 Impact factor: 9.236
Authors: Iina Laitinen; Päivi Marjamäki; Merja Haaparanta; Nina Savisto; V Jukka O Laine; Sanna L Soini; Ian Wilson; Pia Leppänen; Seppo Ylä-Herttuala; Anne Roivainen; Juhani Knuuti Journal: Eur J Nucl Med Mol Imaging Date: 2006-07-15 Impact factor: 9.236
Authors: M Wintermark; S S Jawadi; J H Rapp; T Tihan; E Tong; D V Glidden; S Abedin; S Schaeffer; G Acevedo-Bolton; B Boudignon; B Orwoll; X Pan; D Saloner Journal: AJNR Am J Neuroradiol Date: 2008-02-13 Impact factor: 3.825
Authors: Carmen Burtea; Sophie Laurent; Oltea Murariu; Dirk Rattat; Gérard Toubeau; Alfons Verbruggen; David Vansthertem; Luce Vander Elst; Robert N Muller Journal: Cardiovasc Res Date: 2008-01-03 Impact factor: 10.787
Authors: Iina Laitinen; Päivi Marjamäki; Kjell Någren; V Jukka O Laine; Ian Wilson; Pia Leppänen; Seppo Ylä-Herttuala; Anne Roivainen; Juhani Knuuti Journal: Eur J Nucl Med Mol Imaging Date: 2008-08-19 Impact factor: 9.236
Authors: Max Kiugel; Ingrid Dijkgraaf; Ville Kytö; Semi Helin; Heidi Liljenbäck; Tiina Saanijoki; Cheng-Bin Yim; Vesa Oikonen; Pekka Saukko; Juhani Knuuti; Anne Roivainen; Antti Saraste Journal: Mol Imaging Biol Date: 2014-12 Impact factor: 3.488
Authors: Antti Saraste; Iina Laitinen; Eliane Weidl; Moritz Wildgruber; Axel W Weber; Stephan G Nekolla; Gabriele Hölzlwimmer; Irene Esposito; Axel Walch; Pia Leppänen; Irina Lisinen; Peter B Luppa; Seppo Ylä-Herttuala; Hans-Jürgen Wester; Juhani Knuuti; Markus Schwaiger Journal: J Nucl Cardiol Date: 2012-04-20 Impact factor: 5.952
Authors: Soraya M Kazuma; Deborah Sultan; Yongfeng Zhao; Lisa Detering; Meng You; Hannah P Luehmann; Dulcineia S P Abdalla; Yongjian Liu Journal: Curr Pharm Des Date: 2015 Impact factor: 3.116
Authors: Ingrid Dijkgraaf; Cheng-Bin Yim; Gerben M Franssen; Robert C Schuit; Gert Luurtsema; Shuang Liu; Wim J G Oyen; Otto C Boerman Journal: Eur J Nucl Med Mol Imaging Date: 2010-09-21 Impact factor: 9.236
Authors: Johanna Mu Silvola; Iina Laitinen; Henri J Sipilä; V Jukka O Laine; Pia Leppänen; Seppo Ylä-Herttuala; Juhani Knuuti; Anne Roivainen Journal: EJNMMI Res Date: 2011-08-17 Impact factor: 3.138